Nov 13, 2023
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 07, 2023
NGM Bio to Participate in Upcoming Investor Conferences
Nov 02, 2023
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Oct 11, 2023
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
Aug 03, 2023
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
May 25, 2023
NGM Bio to Participate in Upcoming Investor Conferences
May 08, 2023
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 04, 2023
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
Mar 01, 2023
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
Feb 28, 2023
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 12, 2023
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
Jan 09, 2023
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
Dec 12, 2022
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
Dec 07, 2022
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
Nov 07, 2022
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
Nov 04, 2022
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
Nov 03, 2022
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
Nov 03, 2022
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
Oct 17, 2022
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Oct 16, 2022
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sep 13, 2022
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer
Sep 06, 2022
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress
Aug 15, 2022
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer
Aug 04, 2022
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
Jun 30, 2022
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
Jun 23, 2022
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
Jun 02, 2022
NGM Bio to Participate in Upcoming Investor Conferences
May 24, 2022
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
May 12, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
May 05, 2022
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
Apr 20, 2022
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
Apr 20, 2022
NGM Bio to Participate in Upcoming Investor Conferences
Apr 08, 2022
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
Mar 31, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
Mar 21, 2022
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
Mar 08, 2022
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
Mar 01, 2022
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 28, 2022
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
Feb 07, 2022
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Jan 20, 2022
NGM Bio to Participate in Upcoming Investor Conferences
Jan 10, 2022
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
Jan 06, 2022
NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
Dec 06, 2021
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
Nov 09, 2021
NGM Bio to Participate in Upcoming Investor Conferences
Nov 04, 2021
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
Sep 16, 2021
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
Aug 23, 2021
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
Aug 05, 2021
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
Jul 22, 2021
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Jul 07, 2021
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors
Jul 01, 2021
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
Jun 07, 2021
NGM Bio to Present at Two Upcoming Investor Conferences
May 24, 2021
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 23, 2021
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 06, 2021
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
Apr 28, 2021
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
Mar 04, 2021
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 02, 2021
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
Feb 25, 2021
NGM Bio to Present at the Cowen 41st Annual Health Care Conference
Feb 09, 2021
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
Jan 12, 2021
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
Jan 05, 2021
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
Jan 04, 2021
NGM Bio Announces Proposed Offering of Common Stock
Dec 09, 2020
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
Nov 16, 2020
NGM to Host Virtual R&D Day on December 9, 2020
Nov 13, 2020
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
Nov 12, 2020
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
Nov 11, 2020
NGM Bio to Present at Three Upcoming Investor Conferences
Nov 05, 2020
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
Nov 04, 2020
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
Oct 19, 2020
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
Aug 29, 2020
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
Aug 18, 2020
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
Aug 12, 2020
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
Jul 31, 2020
NGM Bio to Present at Two Upcoming Investor Conferences
Jul 27, 2020
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Jun 08, 2020
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
May 29, 2020
NGM Bio to Present at Two Upcoming Investor Conferences
May 27, 2020
NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer
May 13, 2020
NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results
May 08, 2020
NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
Mar 17, 2020
NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Mar 09, 2020
Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company
Feb 25, 2020
NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference
Feb 24, 2020
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo
Feb 23, 2020
NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH
Feb 11, 2020
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)
Dec 05, 2019
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors
Nov 14, 2019
NGM Bio to Present at the Stifel 2019 Healthcare Conference
Nov 12, 2019
NGM Reports Business Highlights and Third Quarter 2019 Financial Results
Oct 29, 2019
NGM Bio Announces Appointment of Valerie Pierce as General Counsel
Oct 18, 2019
NGM Bio to Present at Upcoming Investor Conferences
Oct 07, 2019
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
Oct 06, 2019
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH
Oct 03, 2019
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®
Aug 12, 2019
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
Jun 10, 2019
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Jun 05, 2019
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
May 16, 2019
NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
Apr 08, 2019
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
Apr 03, 2019
NGM Bio Announces Pricing of Initial Public Offering
Mar 20, 2019
NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer
Mar 20, 2019
Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022
Jan 03, 2019
Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Nov 12, 2018
NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)
Nov 09, 2018
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH
Nov 06, 2018
NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313
Oct 01, 2018
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer
Apr 14, 2018
NGM Bio Announces Results From Phase 2 Study Of NGM282 In Nash Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
Apr 13, 2018
NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Mar 12, 2018
NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Feb 05, 2018
NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
Oct 19, 2017
NGM Bio Provides Update on NGM282 in NASH
Oct 02, 2017
Study Published in Nature Reveals Molecular Pathway of Weight-Controlling Hormone, Enabling the Discovery of Multiple Drug Candidates for Obesity and Cachexia
Apr 22, 2017
NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Apr 05, 2017
NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017
Jun 08, 2016
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH
Nov 09, 2015
NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015
Sep 30, 2015
NGM Bio is named one of FierceBiotech’s “Fierce 15” Biotech Companies of 2015
Mar 24, 2015
NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine
Mar 23, 2015
NGM Biopharmaceuticals Secures $57.5 Million Series D Financing
Mar 02, 2015
NGM Biopharmaceuticals Announces Expansion of Management Team
Feb 23, 2015
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
Jul 18, 2013
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Jul 17, 2013
NGM Biopharmaceuticals and MedImmune, AstraZeneca’s Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Jan 03, 2013
NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes
Mar 28, 2012
NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabete
Oct 04, 2010
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director
Mar 15, 2010
NGM Biopharmaceuticals Raises $51 million in Series B financing and Appoints New Board Member
Oct 21, 2009
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors
Sep 01, 2009
NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer
Feb 11, 2008